Sitryx Therapeutics bags $30m in Series A FinancingOxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and … more ➔
Orchard plans to raise US$172m in ADSBritish gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, Goldman Sachs, Cowen … more ➔
Sphingotec raises €20m in growth equity financingDiagnostics company sphingotec GmbH successfully closed a €20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington … more ➔
Sanofi and Evotec launch drug discovery PPPEvotec and Sanofi have launched a Public Private Partnership (PPP) aimed at partnering with academic groups in early stage drug discovery across multiple therapeutic areas. more ➔
Roche providing improved anti-Her2 bispecific antibodyResearchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds. more ➔
Forbion closes Life Sciences VC Fund at €360mLife Sciences venture capitalist Forbion has closed its new flagship fund, Forbion IV, at €360m, €90m above its original target of €250m. more ➔
BIOSPAIN expandingMatured, diversified and willing to expand – this is how the Spanish biotech sector presented itself during BIOSPAIN 2018 in Seville. Andalusia has launched the first bioeconomy policy strategy in S … more ➔
Minoryx bags €21.3m Series B financingBarcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another €21.3m in a Series B financing bringing its assets to a total of €50M. more ➔
PD-1+ T cells trigger pulmonary fibrosisA team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.&n … more ➔
Roche’s Tecentriq prolongs OS in SCLCCancer immunotherapy has been heralded as paradigm change in cancer treatment. Now, Roche’s US arm Genentech announced that the company’s anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) improved … more ➔
